Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$29.69
-0.58-1.92%
Last update: Dec 15, 2:03 PM
Comments
Loading...
Rapport Therapeutics Analyst Ratings and Price Targets | NASDAQ:RAPP | Benzinga
Rapport Therapeutics Inc has a consensus price target of $43.88 based on the ratings of 9 analysts. The high is $80 issued by Citizens on November 7, 2025. The low is $28 issued by JMP Securities on July 8, 2025. The 3 most-recent analyst ratings were released by HC Wainwright & Co., BTIG, and BTIG on December 9, 2025, December 8, 2025, and November 19, 2025, respectively. With an average price target of $44.67 between HC Wainwright & Co., BTIG, and BTIG, there's an implied 50.44% upside for Rapport Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
BTIG
Citizens
Truist Securities
JMP Securities
1calculated from analyst ratings
Analyst Ratings for Rapport Therapeutics
FAQ
What is the target price for Rapport Therapeutics (RAPP) stock?
The latest price target for Rapport Therapeutics (NASDAQ:RAPP) was reported by HC Wainwright & Co. on December 9, 2025. The analyst firm set a price target for $40.00 expecting RAPP to rise to within 12 months (a possible 34.73% upside). 9 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Rapport Therapeutics (RAPP)?
The latest analyst rating for Rapport Therapeutics (NASDAQ:RAPP) was provided by HC Wainwright & Co., and Rapport Therapeutics maintained their buy rating.
When was the last upgrade for Rapport Therapeutics (RAPP)?
There is no last upgrade for Rapport Therapeutics
When was the last downgrade for Rapport Therapeutics (RAPP)?
There is no last downgrade for Rapport Therapeutics.
When is the next analyst rating going to be posted or updated for Rapport Therapeutics (RAPP)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Rapport Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Rapport Therapeutics was filed on December 9, 2025 so you should expect the next rating to be made available sometime around December 9, 2026.
Is the Analyst Rating Rapport Therapeutics (RAPP) correct?
While ratings are subjective and will change, the latest Rapport Therapeutics (RAPP) rating was a maintained with a price target of $34.00 to $40.00. The current price Rapport Therapeutics (RAPP) is trading at is $29.69, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
